ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

The Value of HER2 neu and EphA2 expressions in Gastric Adenocarcinoma Prognosis

Ola A Harb1*, Hanaa A Atwa1, Rasha Haggag2, Shereen El-Shorbagy2, Lobna A Abdelaziz3, Safa A Balata3, Fady M Habib4 and Loay M Gertallah4

1Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

2Department of Medical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

3Department of Clinical Oncology and nuclear medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt

4Department of General Surgery, Faculty of Medicine, Zagazig University, Zagazig, Egypt

*Corresponding Author:
Ola A Harb
Department of Pathology
Faculty of Medicine, Zagazig University
Zagazig, Egypt
Tel: 01224963123
E-mail: olaharb2015@gmail.com

Received date: March 12, 2017; Accepted date: March 31, 2017; Published date: April 07, 2017

Citation: Harb OA, Atwa HA, Haggag R, El-Shorbagy S, Abdelaziz LA, et al. (2016) The Value of HER2 neu and EphA2 expressions in Gastric Adenocarcinoma Prognosis. J Gastroint Dig Syst 7:498. doi: 10.4172/2161-069X.1000498

Copyright: © 2017 Harb OA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Gastric adenocarcinoma (GAC) is a serious disease with poor outcome. Discovering novel molecular targeted therapies is a recent point of research to improve prognosis. One of the newly discovered targets is the receptor tyrosine kinases (RTKs); it is a member of trans-membrane receptors which had important roles in proliferation and apoptosis. RTKs were found to have different expression patterns in several malignancies. HER2 neu which is a member of HER family is a proto-oncogene that is formed of four receptor tyrosine kinases. Erythropoietinproducing hepatocellular (Eph) molecules are major RTKs members and one of those molecules is EphA2 which has many different functions in cancer as tumor initiation, progression, angiogenesis and spread. We aimed to explore the expression patterns of both HER2 neu and EphA2 in GAC patients using immunohistochemistry, and to correlate their expressions with clinico-pathological factors and prognosis of our patients Methods: HER2 neu and EphA2 expressions were assessed in sections from forty blocks of paraffin which were diagnosed as GAC. Then we analyzed the correlations between their expressions and disease outcome of GAC patients. Results: HER2 neu and EphA2 positive expressions in GAC were positively correlated with tumor grade and stage (p<0.001 and p=0.002 respectively), inadequate response to therapy (p<0.001 and p=0.002 respectively), increase recurrence rate of GAC (p=0.002), and with poor survival (p<0.001). Conclusion: GAC patients with high expressions of both HER2 neu and EphA2 had unfavorable prognosis.

Keywords

Top